Angiotensin systems and experimental renal diseases
Read Online

Angiotensin systems and experimental renal diseases proceedings by Conference on the Kidney (14th 1962)

  • 146 Want to read
  • ·
  • 87 Currently reading

Published by Little, Brown in Boston .
Written in English


  • Kidneys -- Diseases -- Congresses,
  • Angiotensins

Book details:

Edition Notes

Statementfourteenth annual Conference on the Kidney ; edited by Jack Metcoff
ContributionsMetcoff, Jack, 1917-, National Kidney Disease Foundation
The Physical Object
Paginationxv, 268 p. :
Number of Pages268
ID Numbers
Open LibraryOL14602665M
LC Control Number63021909

Download Angiotensin systems and experimental renal diseases


Jul 01,  · Angiotensin Systems and Experimental Renal Diseases. (PMCID:PMC) Abstract Citations; Related Articles; Data; BioEntities; External Links ' ' Spencer AG Proceedings of the Royal Society of Medicine [01 Jun , 57(6)] Type: book-review, Book Review. A G Spencer. May 18,  · The existence of local or tissue-based renin-angiotensin-aldosterone systems (RAAS) is well documented and has been implicated as a key player in the pathogenesis of cardiovascular and renal diseases. The kidney contains all elements of the RAAS, and Cited by: Jun 30,  · Introduction. The systemic role of the renin-angiotensin system (RAS) in the regulation of blood pressure and volume homeostasis and in the pathophysiology of hypertension (HTN) has been targeted for many decades1).Increased RAS activity is also a major determinant for numerous pathologic conditions because angiotensin II (Ang II) increases aldosterone and blood pressure and contributes Cited by: Apr 13,  · The proceedings of the Fourteenth Annual Conference on the Kidney () sponsored by the National Kidney Disease Foundation, recently published in a new and attractive format, maintain the standard of excellence of previous first part of Cited by: 9.

The Two fACEs of the Tissue Renin-Angiotensin Systems: Implication in Cardiovascular Diseases Author(s): Eric Lazartigues, Yumei Feng, Julie L. Lavoie. Louisiana State University Health Sciences Center, Department of Pharmacology and Experimental Therapeutics, Perdido Street P, New Orleans, LA , by: Manuel T. Velasquez, in Chronic Renal Disease, Renin-Angiotensin-Aldosterone System Inhibitors. Renin-angiotensin-aldosterone system (RAAS) inhibitors, namely ACEIs and ARBs, have been the most studied antihypertensive agents in CKD, and are recommended as first choice in . Experimental and clinical evidence supports an active role of the renin–angiotensin system (RAS) in the pathogenesis and progression of lung diseases. Angiotensin II (Ang II), a key vasoactive peptide of the RAS, has been implicated in pulmonary disorders such as pulmonary arterial hypertension, lung fibrosis, chronic obstructive pulmonary. The idea of publishing a book on the new aspects of the renin-angiotensin system (RAS) in cardiovascular and renal diseases has been developed during the past few years. The need for a book that describes the new approaches of the RAS in the development of cardiovascular and renal diseases and the trend of future research became apparent.

Download PDF: Sorry, we are unable to provide the full text but you may find it at the following location(s): prideinpill.comg (external link)Author: A G Spencer. Angiotensin-converting enzyme (EC ), or ACE, is a central component of the renin–angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. It converts the hormone angiotensin I to the active vasoconstrictor angiotensin prideinpill.comore, ACE indirectly increases blood pressure by causing blood vessels to BRENDA entry. High concentrations of Angiotensin II can constrict the glomerular mesangium, reducing the area for glomerular filtration. Angiotensin II is a sensitizer to tubuloglomerular feedback, preventing an excessive rise in GFR. Angiotensin II causes the local release of prostaglandins, which, in External IDs: GeneCards: [1]. Clinical Import of the Local Renin Angiotensin Aldosterone Systems. still of innovative and imaginative clinical and experimental studies. pertains to cardiovascular and renal diseases.